EP Wealth Advisors LLC Trims Stake in Danaher Co. (NYSE:DHR)

EP Wealth Advisors LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 10.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,303 shares of the conglomerate’s stock after selling 2,425 shares during the quarter. EP Wealth Advisors LLC’s holdings in Danaher were worth $4,697,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. Geo Capital Gestora de Recursos Ltd lifted its stake in Danaher by 160.5% during the fourth quarter. Geo Capital Gestora de Recursos Ltd now owns 12,235 shares of the conglomerate’s stock worth $2,830,000 after purchasing an additional 7,539 shares during the last quarter. Zeno Equity Partners LLP bought a new stake in Danaher during the fourth quarter worth about $24,740,000. Beaird Harris Wealth Management LLC lifted its stake in Danaher by 10.1% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 655 shares of the conglomerate’s stock worth $152,000 after purchasing an additional 60 shares during the last quarter. Syon Capital LLC lifted its stake in Danaher by 54.7% during the fourth quarter. Syon Capital LLC now owns 6,960 shares of the conglomerate’s stock worth $1,610,000 after purchasing an additional 2,460 shares during the last quarter. Finally, Centaurus Financial Inc. lifted its stake in shares of Danaher by 2.1% in the 4th quarter. Centaurus Financial Inc. now owns 6,153 shares of the conglomerate’s stock valued at $1,423,000 after acquiring an additional 127 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE DHR traded down $0.16 on Friday, reaching $254.85. 3,097,194 shares of the stock were exchanged, compared to its average volume of 2,930,997. The company’s 50-day simple moving average is $253.48 and its two-hundred day simple moving average is $244.13. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $188.76 billion, a PE ratio of 43.19, a PEG ratio of 3.90 and a beta of 0.85. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHRGet Free Report) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the business posted $2.36 earnings per share. The firm’s revenue was down 2.6% on a year-over-year basis. Analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Insider Activity

In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last ninety days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HSBC raised Danaher from a “hold” rating to a “buy” rating and boosted their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Jefferies Financial Group assumed coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Bank of America upped their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Finally, TD Cowen upped their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $269.29.

View Our Latest Report on Danaher

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.